A B S T R A C T
Background. We investigated whether initial population screening for elevated albuminuria with subsequent screening for hypertension in case albuminuria is elevated may be of help to identify subjects at risk for accelerated decline in kidney function. Methods. We included subjects who participate in the PREVEND observational, general population-based cohort study and had two or more glomerular filtration rate (eGFR) measurements available during follow-up. Elevated albuminuria was defined as an albumin concentration !20 mg/L in a first morning urine sample confirmed by an albumin excretion !30 mg/day in two 24-h urines. Hypertension was defined as systolic blood pressure !140 mmHg, diastolic blood pressure !90 mmHg or use of blood pressure-lowering drugs. eGFR was estimated with the CKD-EPI creatinine-cystatin C equation. Results. Overall, 6471 subjects were included with a median of 4 [95% confidence interval (CI) 2-5] eGFR measurements during a follow-up of 11.3 (95% CI 4.0-13.7) years. Decline in eGFR was greater in the subgroups with elevated albuminuria. This held true, not only in subjects with known hypertension (À1.84 6 2.27 versus À1.16 6 1.45 mL/min/1.73 m 2 per year, P < 0.05), but also in subjects with newly diagnosed hypertension (À1.59 6 1.55 versus À1.14 6 1.38 mL/min/1.73 m 2 per year, P < 0.05) and in subjects with normal blood pressure (À1.18 6 1.85 versus À0.81 6 1.02 mL/min/1.73 m 2 per year in subjects, P < 0.05). This effect was most pronounced in the population !55 years of age and male subjects. In addition, subjects with elevated albuminuria had higher blood pressure than subjects with normoalbuminuria, and in subjects with elevated albuminuria as yet undiagnosed hypertension was twice as prevalent as diagnosed hypertension. Conclusions. Initial screening for elevated albuminuria followed by screening for hypertension may help to detect subjects with increased risk for a steeper decline in kidney function.
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I N T R O D U C T I O N
End-stage kidney disease (ESKD) for which renal replacement therapy (RRT) is needed is a major health problem for affected patients, not only because of the medical and psychological consequences, but also for society at large, because of the high associated costs. The number of subjects requiring RRT is still increasing [1] . Most patients reach ESKD not due to an acute event, but because of a chronic, gradual decline of kidney function over decades. In most western countries, the primary causes of ESKD are diabetes, hypertension or renal vascular disorders [2] . This is remarkable, because it has been well demonstrated that angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), preferably in combination with diets low in salt and/or in protein, can prevent progressive renal function decline, especially in subjects with elevated albuminuria [3] [4] [5] [6] [7] . The discrepancy between availability of effective renoprotective treatments and increasing numbers of patients starting RRT is at least partly caused by the fact that the early stages of chronic kidney disease (CKD) are generally asymptomatic, and consequently remain underdiagnosed and untreated.
It has been well demonstrated that elevated albuminuria and high blood pressure are the two most important risk factors for progressive loss of kidney function [8] [9] [10] . In a previous study, we showed that population screening for elevated albuminuria results in identification of a subpopulation with a high percentage of previously unknown cardiovascular (CV) risk factors [11] . In addition, it appeared that subjects who were identified to have elevated albuminuria and previously unknown hypertension were at such a high risk for CV events that they were likely to benefit from starting treatment to prevent CV events [12] .
In the present study, we questioned whether screening for elevated albuminuria followed by screening for hypertension could also be of help to identify those patients who in the long run will show accelerated renal function decline. Secondly, we were interested in the efficacy of this screening approach in older subjects, because it has been suggested that screening of older subjects for albuminuria might be cost-effective to reduce the incidence of ESKD and CV events [13] . To address these questions we used long-term follow-up data of the PREVEND study.
M A T E R I A L S A N D M E T H O D S

Study design and population
This analysis uses data of the PREVEND study, a prospective observational cohort study designed to investigate the association of albuminuria with renal and CV disease progression in the general population. The design of the PREVEND study has been described in detail elsewhere [14] . In summary, participating subjects were selected in 1997 from 40 856 individuals from the general population in whom albuminuria was measured. A cohort aged 20-75 years, enriched for higher levels of albuminuria, was drawn from these individuals. Overall, 8592 subjects [n ¼ 6000 with a urinary albumin concentration (UAC) in a first morning void urine sample of ! 10 mg/L and n ¼ 2592 with a UAC < 10 mg/L] gave written informed consent and were included in the baseline screening between 1997 and 1998. The PREVEND study has been approved by the institutional medical ethics committee and is conducted in accordance with the International Conference of Harmonization Good Clinical Practice Guidelines and adheres to the ethical principles that have their origin in the Declaration of Helsinki.
Participants were invited to visit a study outpatient clinic every 3-4 years for measurements of renal and CV risk factors and outcomes. Since we wanted to study a non-diabetic population without known kidney disease, subjects with self-reported diabetes (n ¼ 142) or known kidney disease (n ¼ 22) at baseline were excluded. In addition, because change in kidney function is the primary outcome in this study, participants with only one measurement of serum creatinine and/or serum cystatin C were excluded (n ¼ 1957). Thus, the present study population consists of 6471 subjects.
Measurements and definitions
During each screening round participants visited an outpatient clinic twice. During these visits subjects filled in a questionnaire (regarding demographics, smoking habits, disease history and use of medication), a physical examination was performed (including measurement of weight, height and blood pressure), fasting blood was drawn and subjects collected urine samples. Data on medication use was furthermore obtained from the IADB database (www.IADB.nl), which comprises dispensing data of community pharmacists located in the northern part of the Netherlands [15] .
During each screening round subjects were asked to collect two 24-h urine samples on consecutive days. Participants were instructed not to collect urine in case of fever and to refrain from intensive physical activity during the collection period. UAC was measured by nephelometry with a threshold of 2.3 mg/L and intra-and interassay coefficients of variation of 2.2 and 2.6%, respectively. Urinary albumin excretion (UAE) and albumin-to-creatinine ratio are given as the mean of the two 24-h urine collections. Elevated albuminuria was defined as an albumin concentration !20 mg/L in the first morning urine sample confirmed by an albumin excretion !30 mg/day in two 24-h urines.
During both visits at the baseline screening, blood pressure was measured with an automatic device (Dinamap XL Model 9300, Johnson & Johnson Medical, Tampa, FL, USA) in supine position over 10 min. Systolic and diastolic blood pressure was calculated as the mean of the last two measurements at both occasions. Hypertension was defined as systolic blood pressure !140 mmHg, diastolic blood pressure !90 mmHg or the use of antihypertensive medication [16, 17] . Hypertension was considered to be known when the subject involved reported use of blood pressure-lowering medication or was known to use such medication from pharmacy records.
From the fasting blood samples concentrations of total cholesterol and plasma glucose were measured using standard methods. Serum cystatin C level was measured by nephelometry, the intra-and interassay coefficients of variation were-<4.1% and <3.3%, respectively (BN II; Dade Behring Diagnostic, Marburg, Germany). Serum creatinine was measured by dry chemistry (Eastman Kodak, Rochester, NY, USA), with intra-and interassay coefficients of variation of 0.9% and 2.9%, respectively. The measurements of cystatin C and creatinine were both calibrated against international standards. Creatinine and cystatin C were measured after the fifth screening visit in samples that had been stored frozen at -80 C, with all samples for a single subject being assessed on the same day immediately after each other to minimize variation in creatinine and cystatin C concentration that can be caused by inter assay variability and drift in analyte measurements [18] . Glomerular filtration rate (eGFR) was estimated with the CKD-EPI creatinine-cystatin C equation, taking into account sex, age, race, serum creatinine and cystatin C [19, 20] .
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Statistical analyses
To assess the association of elevated albuminuria and hypertension with annual change of eGFR, we divided our study population into six subgroups according to baseline albuminuria (normal or elevated) and hypertension status (absent, newly discovered or known). Baseline characteristics of these groups were compared. Continuous data are reported as mean and standard deviation. In case of a skewed distribution, median and IQR presented, the reference range is 2.5% to 97.5% percentile. Prevalences are reported as percentages. To calculate differences between the various subgroups v 2 tests were used for categorical data, and for continuous data Student's t-tests or a Mann-Whitney rank test in case of skewed distribution.
To calculate annual change in eGFR per individual a linear regression line was drawn through all available eGFR values. In cases where only two measurements were available, change in eGFR was used (last eGFR minus first eGFR divided by duration of follow-up). The rate of change in eGFR was compared across the six subgroups defined according to albuminuria and hypertension status. Various sensitivity analyses were performed to examine the robustness of our primary analysis. First, to study the association of baseline hypertension and albuminuria status with annual change in eGFR during follow-up, slopes of eGFR-creatinine and of eGFR-cystatin C over time were calculated separately, respectively, estimated with the CKD-EPI creatinine and the CKD-EPI cystatin C equations, instead of using eGFR estimated by creatinine and cystatin C combined [19, 20] . Next we performed the same analysis in subjects in whom slopes, were assessed by means of regression analysis, thus excluding subjects with only two eGFR values available. As ACE inhibitors and ARBs may lower blood pressure and albuminuria, and influence the course of eGFR over time, we studied the course of eGFR in those subjects that during follow-up did not use any of these drugs (i.e. we censored patients at start of use). Finally, we performed the same analyses subdividing the study population according to gender and to age < 55 and !55 years as it has previously been suggested that, in addition to screening the accepted high risk groups of patients with known hypertension and diabetes, it might be cost-effective to screen older subjects for CKD [9, 21, 22] .
To estimate annual change in eGFR, we also conducted a longitudinal linear mixed model analysis. Based on model fit criteria and likelihood ratio statistics where appropriate, we defined a model with random intercept, random slope and unstructured covariance matrix. The number of subjects was higher, because in this analysis all data could be used, without the necessity to exclude subjects with less than two measurements available. To compare slopes between risk categories, two-way interaction terms between risk categories and time were introduced and tested. Continuous variables are presented as means 6 standard deviation and urinary albumin creatinine ratio and urinary albumin excretion as median value (95% IQR). eGFR was estimated with the CKD-EPI creatinine-cystatin C equation [19, 20] . HT, hypertension; n, number; BMI, body mass index; BP, blood pressure; NA, not applicable; IQR, interquartile range. *P < 0.05; versus normoalbuminuria and no HT subgroup. † P < 0.05; versus respective normoalbuminuria subgroup. ‡ P < 0.05; versus no HT elevated albuminuria subgroup.
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All statistical analyses were conducted with the use of the statistical package IBM SPSS (version 22.0; IBM, Chicago, IL, USA). All P-values are two-tailed, and P-values <0.05 were considered statistically significant.
R E S U L T S
The 6471 subjects included in the present analyses had a median follow-up of 11.3 [95% confidence interval (CI) 4.0-13.7] year, and had a median number of eGFR measurements of 4 (95% CI 2-5). In 5573 subjects, three or more eGFR measurements were available. Table 1 shows the baseline characteristics of the 6471 included subjects, subdivided according to albuminuria and hypertension status. Elevated albuminuria was seen in 9.3% of the subjects, and hypertension in 28.6%. Of the hypertensive subjects, 10.1% was known to be hypertensive, whereas the majority (18.5%) was newly diagnosed to be hypertensive at the baseline screening. In each of the three blood pressure subgroups (i.e. no hypertension, new hypertension, known hypertension) the subjects with elevated albuminuria were older, more often male and had a more unfavourable CV risk profile when compared with their normoalbuminuric counterparts. Importantly, in the subgroups of subjects with elevated albuminuria those with new and known hypertension had higher systolic and diastolic blood pressure than in the corresponding blood pressure groups with normoalbuminuria, indicating that in subjects with elevated albuminuria and known hypertension, blood pressure was poorly controlled. The subjects with elevated albuminuria also had higher baseline serum creatinine and cystatin C values, and consequently a lower eGFR and more frequently a worse CKD stage. Table 2 shows eGFR at baseline and during follow-up. At baseline, eGFR was lower in subjects with elevated as compared with normal albuminuria, and similarly per albuminuria subgroup, eGFR was lower in the groups with hypertension versus those without. During follow-up the largest fall in eGFR was observed in the subgroups with elevated albuminuria and known or new hypertension (À13.9 and À13.7 mL/min/ 1.73 m 2 , respectively). In Figure 1 , annual change in eGFR during follow-up is presented for the various subgroups. In the four hypertensive subgroups, the subjects with elevated albuminuria always had a faster rate of eGFR decline than the respective subgroups with normoalbuminuria. Moreover, in both albuminuria subgroups, the subjects with known, but also those with newly diagnosed hypertension, had a more negative eGFR slope than those with normal blood pressure.
Similar results of eGFR decline were obtained by carrying out a mixed model analysis for repeated measurements (Table  3) . Also, the sensitivity analyses with the CKD-EPI eGFR equations that incorporate only creatinine or only cystatin C showed similar differences between the elevated and normal albuminuria subgroups and the three hypertensive subgroups when compared with our primary analysis. When only taking into account the 5573 subjects with three or more creatinine and cystatin C measurements, in which regression analysis could be performed to assess annual change in eGFR, again similar results were obtained as in the overall analysis that included data of 6471 subjects.
Of note, 1340 subjects at any time during follow-up used an ACE inhibitor and/or an ARB. In the 5131 subjects who never used an ACE inhibitor and/or an ARB, the differences between the various subgroups in annual change in eGFR were again comparable to the difference in the primary analysis. In this last analysis, however, the number of subjects in the elevated albuminuria subgroups with hypertension was limited, presumably because these classes of drugs are preferentially prescribed to subjects with hypertension, elevated albuminuria and kidney function loss. Table 4 shows the results of analyses in subjects stratified by age and gender. The baseline characteristics of subjects stratified . eGFR was estimated with the CKD-EPI creatinine-cystatin C equation [19, 20] . Follow-up is presented as median value (95% CI). HT, hypertension; n, number.
S c r e e n i n g f o r p e o p l e t h a t n e e d r e n o p r o t e c t i v e t r e a t m e n t Tables S1 and S2 . Although the change in kidney function over time was not significantly different between subjects <55 years with elevated albuminuria and subjects <55 years without elevated albuminuria, the fall in GFR was more pronounced in the former than in the latter (Table 4) . Also, the prevalence of subjects with elevated albuminuria was higher in the !55 years subgroup than in the <55 years subgroup (16.4% versus 6.0%). In addition, the prevalence of known as well as newly discovered hypertension was highest among subjects !55 years old and with elevated albuminuria. Elevated albuminuria was more often seen in men, and the annual eGFR decline was more pronounced in men than in women.
D I S C U S S I O N
In this study, we showed that decline in eGFR was significantly more pronounced in subjects with elevated albuminuria, not only in those with known hypertension, but also in subjects with previously unknown hypertension. In the subjects with elevated albuminuria and known hypertension blood pressure was poorly controlled, but the highest blood pressure was found in subjects with elevated albuminuria and as yet unknown hypertension. The prevalence of this latter condition was twice as high as that of elevated albuminuria and known hypertension. Identifying subjects at an early stage of CKD may be of help to prevent ESKD because the risk factors hypertension and albuminuria can be treated. As such, our data indicate that population screening for albuminuria may be of help to identify subjects at risk for accelerated kidney function decline during follow-up that may benefit from treatment. Change in eGFR during follow-up for the study population subdivided according to baseline albuminuria and hypertension status (mean and interquartile range). *P < 0.05, versus normoalbuminuria and no hypertension subgroup.ˆP < 0.05, versus respective normoalbuminuria subgroup. 0 P < 0.05, versus elevated albuminuria and no hypertension subgroup. Change in eGFR is presented as mean 6 standard deviation. eGFR, eGFR-creatinine and eGFR-cystatin C were, respectively, estimated with the CKD-EPI creatinine-cystatin C, CKD-EPI creatinine and CKD-EPI cystatin C equations [19, 20] . HT, hypertension; n, number; SD, standard deviation; RAASi, renin-angiotensin-aldosterone system inhibition. *P < 0.05; versus normoalbuminuria and no HT subgroup. † P < 0.05; versus respective normoalbuminuria subgroup. ‡ P < 0.05; versus no HT elevated albuminuria subgroup. At present, much attention is being given to the possible benefits of screening for CKD, as CKD is not only related to ESKD, but also to progressive CV disease, and is thus associated with high costs. The generally accepted approach is to screen highrisk groups like patients known with diabetes mellitus or hypertension [21, 23] . Hoerger et al. showed that microalbuminuria screening is cost-effective for patients with diabetes or hypertension, but may not be cost-effective for subjects with neither diabetes nor hypertension [24] . This is in line with our finding that the subjects with elevated albuminuria and known hypertension had the highest rate of eGFR loss during follow-up. In subjects with elevated albuminuria and newly diagnosed hypertension (which was twice as prevalent as known hypertension), the rate of eGFR decline was only slightly less pronounced. Also, in normotensive subjects with elevated albuminuria the rate of eGFR decline was significantly steeper than in normotensive normoalbuminuric subjects. In that respect, it is of interest that Hoerger et al. showed that screening for CKD in normotensive and non-diabetic subjects could be cost-effective, when it is performed at longer intervals or as part of regular physicians visits [24] . Our findings are in agreement with data by Clark et al., who showed that baseline albuminuria or dipstick proteinuria are predictive for the decline in kidney function in a 7-year follow-up study in Western Ontario, Canada [9] . They showed that an elevated albuminuria in a fully adjusted model was associated with a 1.53 (1.09-2.17) fold increased risk of developing progressive CKD.
In our general population-based study, the absolute risk for ESKD was not studied but would probably be low during the average follow-up of 11.3 years, and screening will not be costeffective to prevent this specific outcome. During longer followup the number of ESKD cases is expected to increase, but will still be limited. However, most subjects with elevated albuminuria also had hypertension at baseline, either as yet undiagnosed or known, but both poorly regulated. These subjects may benefit from start or intensification of blood pressure-lowering treatment to prevent CV events. It is now well accepted that subjects with elevated albuminuria are at especially increased risk for such adverse outcomes [25] . Consequently, in subjects with elevated albuminuria lower blood pressure goals are aimed for than in normoalbuminuric subjects [26] . In addition, data from the PREVEND-IT study suggest that even in normotensive subjects, screening for elevated albuminuria plus subsequent treatment of positive subjects with ACE inhibition is likely to be cost-effective because of its effect to prevent CV events [27] .
Besides the fact that elevated albuminuria and hypertension at baseline are important to predict prognosis with respect to renal and CV outcome, it has recently been shown that change in eGFR adds prognostic value. Using data from the Alberta Kidney Disease Network, Turin et al. showed that declines in eGFR were strongly and consistently associated with increased risk of ESKD and CV events, and that these associations were independent of baseline characteristics [28, 29] . The findings were confirmed in a meta-analysis by the CKD Prognosis Consortium, which included data for 1.7 million participants with 12 344 ESKD events and 223 944 deaths [30] . A screening strategy that identifies subjects with elevated albuminuria and hypertension who show accelerated renal function loss during follow-up, may, therefore, be expected to disclose subjects at especially high risk for adverse health outcomes. In the baseline characteristics (Table 1) , it is also shown that the variables for metabolic syndrome were worse in these subgroups. In this Change in eGFR is presented as mean 6 standard deviation. eGFR was estimated with the CKD-EPI creatinine-cystatin C equation [19, 20] . HT, hypertension; n, number; SD, standard deviation. *P < 0.05; versus normoalbuminuria and no HT subgroup. context, van der Velde et al. described that elevated albuminuria has added value to these variables in predicting new-onset CKD [31] . The prevalence of elevated albuminuria and hypertension in our study was, as expected, higher in older subjects. These subjects also showed higher rates of eGFR loss during follow-up. These data add to the body of evidence which indicates that screening for CKD should target, besides subjects with known diabetes or known hypertension, also elderly subjects. Hoerger et al. calculated that if albuminuria-based CKD screening can be conducted so that the incremental cost of screening is only the cost of the test, initiating screening of persons without diabetes and hypertension is expected to be cost-effective [24] . Interestingly, population screening for colorectal cancer is being implemented in various countries and regions across Europe. In these screening programmes, generally subjects >55 years are asked to send once every 2 years a test tube containing a faeces sample by post to a central laboratory for Faecal Occult Blood Testing [32] [33] [34] . Addition of a test tube to collect a urine sample that allows for determination of albuminuria to this procedure would not lead to significant incremental costs, and thus would meet the requirement defined by Hoerger et al. [24] . For this reason, we used 55 years of age as cut-off to perform subgroup analyses according to age, and found a higher effectiveness of screening in the older subgroup. Based on these data and aforementioned considerations, we make a plea for the investigation of the possibility of combining home-based population screening for colorectal cancer and CKD. This approach should be additional to the conventional screening for CV risk in subjects with hypertension. Of note, the PEVEND study was designed for scientific reasons as pre-screening based on albuminuria measurement in an early morning void urine sample, followed by confirmation by UAE measurement in two 24-h urine samples. For obvious reasons in a large-scale screening, confirmation by measurement of albumin-to-creatinine ratio in two additional early morning void urine samples is to be preferred.
Limitations of our current study are, first, the observational design. Our study is, therefore, hypothesis generating rather than hypothesis testing. Secondly, in this study, which started at a time when ACE inhibitors were not yet used as frequently as nowadays, we could not evaluate the effect of such drugs on kidney disease progression. As the start and cessation of ACE inhibitors and ARBs was not regulated per protocol, and as these antihypertensive and albuminuria-lowering drugs may lead to opposing acute (a reversible, haemodynamic decrease in GFR) and chronic (stabilization of long-term GFR loss) effects on kidney function, we evaluated in a sensitivity analysis whether exclusion of subjects using or starting such agents would influence our conclusions. That, however, was not the case. Thirdly, decline in eGFR can be non-linear in some subjects. However, on a population level the average eGFR decline is linear, for which reason we used linear regression analysis to test our results. The average eGFR decline in the various subgroups may appear relatively low, but we identified subgroups with an approximately 2-fold more rapid decline as the subgroup without elevated albuminuria and without hypertension. On a population level such limited effects may have serious consequences. Fourthly, as non-renal factors may also influence serum creatinine and cystatin C levels, one could question whether our data correctly point to differences in kidney function course. However, as the factors influencing serum creatinine (sarcopenia) are different from the ones with impact on cystatin C (inflammation), we argue that the similarity in the results between the analyses with creatinine-based eGFR and with cystatin C-based eGFR argue for a real effect of albuminuria on true kidney function decline. Fifthly, measurement of GFR by infusion of exogenous tracers, such as iohexol or iothalamate, may be more accurate than eGFR. However, such 'goldstandard' measured GFR (mGFR) has its own limitations [35] and serial mGFR measurements are unfeasible in large-scale epidemiological studies, such as PREVEND. Finally, in this study we did not take into account the impact of having albuminuria on CV events. It is well known that subjects in especially the earlier stages of CKD are at higher risk of experiencing a CV event than of reaching ESKD. In a previous report, we showed that screening for albuminuria and subsequent screening for CV risk factors also identifies subjects at high risk for CV events in which treatment is warranted [12] .
Strengths of our study are first, that our study population is relatively large, with extensive information on renal and CV risk profiles. Secondly, the subjects are followed with eGFR measurements every 3 years for an overall period of more than 11 years. Thirdly, eGFR slopes were constructed from three to five serum creatinine and cystatin C measurements assessed in a central laboratory, with all samples per individual measured in one run. This approach prevents dayto-day variations in measurement of these analyses. In addition, albuminuria was measured in fresh urine samples instead of in samples that had been stored frozen for prolonged periods of time, as in many epidemiological studies. It is known that albuminuria measurement from frozen samples leads to a decrease in average albumin concentration and an increase in variability of albumin measurement [36] . Moreover, in line with prevailing guidelines, elevated albuminuria was assessed not only in one spot sample, but confirmed by two subsequent 24-h urine samples, and also blood pressure was measured on two separate days with an automatic device. These conditions make the PREVEND study uniquely fit for renal epidemiological studies.
In conclusion, based on these data, we conclude that screening for elevated albuminuria, with subsequent clinical assessment of hypertension in case subjects are found positive, is a screening strategy that may result in important public health gain. Subjects with increased risk for steeper decline in kidney function are detected. The efficacy of this screening approach is higher in subjects who are !55 years and male subjects. Detection of these subjects is the more important, because eGFR decline is in itself a risk factor for ESKD and CV events [26] . Formal, large, prospective implementation studies are yet to be carried out, but at present population screening for albuminuria, for instance in combination with colorectal cancer screening, is a tempting option. Those subjects with elevated albuminuria already known with hypertension may benefit from more aggressive renoprotective treatment, whereas in previously unknown hypertensive subjects such treatment can be started in an early phase to prevent kidney function decline. 
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